Markets
markets

Moderna rises, reaching highest price since March

Moderna is up more than 11% on seemingly no news beyond positive trial data for its experimental flu vaccine over a week ago.

The company, which still makes most of its revenue from declining COVID-19 vaccine sales, has been looking for a glimmer of hope as it learns to deal with an administration hostile to vaccines. The company is now up 20% since it announced the results last Monday, but is still down over 20% for the year.

More Markets

See all Markets

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.